## In the Claims:

## 1. (Previously Presented) A compound of the general formula I

where

 $R^{p}$  and  $R^{q}$  are each independently selected from hydrogen, halogen, optionally substituted  $C_{1}\text{-}C_{6}\text{-}alkyl,\ C_{3}\text{-}C_{6}\text{-}cycloalkyl,\ C_{2}\text{-}C_{6}\text{-}alkenyl,\ C_{2}\text{-}C_{6}\text{-}alkynyl,\ C_{1}\text{-}C_{6}\text{-}alkoxy,\ C_{3}\text{-}C_{6}\text{-}cycloalkyloxy,\ C_{3}\text{-}C_{6}\text{-}cycloalkyl-}C_{1}\text{-}C_{4}\text{-}alkyloxy and optionally substituted phenyl;}$ 

W is O, S or an N-R<sup>z</sup> group where R<sup>z</sup> is selected from optionally substituted  $C_1$ - $C_6$ -alkyl,  $C_3$ - $C_6$ -cycloalkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_1$ - $C_6$ -alkoxy,  $C_3$ - $C_6$ -cycloalkyloxy,  $C_3$ - $C_6$ -cycloalkyl- $C_1$ - $C_4$ -alkyloxy and optionally substituted phenyl

and \* denotes the bonding sites;

represents a single bond or a double bond;

 $R^v$ ,  $R^w$  are each independently hydrogen, halogen, optionally substituted  $C_1$ - $C_6$ -alkyl,  $C_1$ - $C_6$ -alkoxy,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_3$ - $C_6$ -cycloalkyloxy,

C<sub>3</sub>-C<sub>6</sub>-cycloalkyl-C<sub>1</sub>-C<sub>4</sub>-alkyloxy or C<sub>3</sub>-C<sub>6</sub>-cycloalkyl;

 $R^x$ ,  $R^y$  are each independently hydrogen, halogen, optionally substituted  $C_1$ - $C_6$ -alkyl,  $C_1$ - $C_6$ -alkoxy,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_3$ - $C_6$ -cycloalkyloxy,  $C_3$ - $C_6$ -cycloalkyl- $C_1$ - $C_4$ -alkyloxy or  $C_3$ - $C_6$ -cycloalkyl, or

 $R^x$ ,  $R^y$ , together with the carbon atoms to which they are bonded, may also form a fused phenyl ring or a fused 5- or 6-membered aromatic heterocycle which has 1, 2, 3 or 4 heteroatoms which are selected from N, O and S, where the fused phenyl ring and the fused aromatic heterocycle may have 1, 2 or 3 substituents which are selected from optionally substituted  $C_1$ - $C_6$ -alkyl, CN,  $OR^1$ ,  $NR^2R^3$ ,  $NO_2$ ,  $SR^4$ ,  $SO_2R^4$ ,  $SO_2NR^2R^3$ ,  $CONR^2R^3$ ,  $COOR^5$ ,  $COR^6$ ,  $C_1$ - $C_4$ -haloalkoxy,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkenyloxy,  $C_2$ - $C_6$ -alkynyl,  $C_3$ - $C_6$ -cycloalkyl,  $C_3$ - $C_6$ -cycloalkyloxy and halogen; where

 $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are each independently H, optionally substituted  $C_1$ - $C_6$ -alkyl or optionally substituted phenyl, where  $R^3$  may also be a  $COR^7$  group where  $R^7$  is hydrogen, optionally substituted  $C_1$ - $C_4$ -alkyl or optionally substituted phenyl, where  $R^2$  with  $R^3$  may also together form a 5- or 6-membered, saturated or unsaturated carbocycle which may have a heteroatom selected from O, S and  $NR^8$  as a ring member, where  $R^8$  is hydrogen or  $C_1$ - $C_4$ -alkyl.

D is a linear or branched 2- to 10-membered alkylene chain which may have, as chain members, a heteroatom group K which is selected from O, S, S(O), S(O)<sub>2</sub>, N-R<sup>8</sup>, CO-O, C(O)NR<sup>8</sup>, and/or 1 or 2 nonadjacent carbonyl groups and which may include a cycloalkanediyl group and/or may have a double or triple bond;

is a saturated or monounsaturated, monocyclic nitrogen heterocycle having from 5 to 8 ring members or a bicyclic saturated nitrogen heterocycle having from 7 to 12 ring members, where the mono- and the bicyclic nitrogen heterocycle optionally has, as a ring member, a further heteroatom selected from oxygen, sulfur or nitrogen, where the mono- or bicyclic nitrogen heterocycle may be unsubstituted or bears an R<sup>a</sup> radical, where

R<sup>a</sup> is  $C_1$ - $C_{10}$ -alkyl,  $C_2$ - $C_{10}$ -alkenyl,  $C_1$ - $C_{10}$ -alkoxycarbonyl,  $C_1$ - $C_{10}$ -alkylcarbonyl,  $C_1$ - $C_{10}$ -alkylsulfonyl,  $C_1$ - $C_{10}$ -cyanoalkyl,  $C_3$ - $C_{10}$ -

cycloalkyl,  $C_3$ - $C_{10}$ -cycloalkyl- $C_1$ - $C_4$ -alkyl,  $C_3$ - $C_{10}$ -cycloalkylcarbonyl,  $C_3$ - $C_{10}$ -cycloalkylcarbonyl- $C_1$ - $C_4$ -alkyl, phenylcarbonyl, phenylcarbonyl- $C_1$ - $C_4$ -alkyl, phenoxycarbonyl, phenyl- $C_1$ - $C_{10}$ -alkyloxycarbonyl, 3- to 8-membered heterocyclylcarbonyl or 3- to 8-membered heterocyclylcarbonyl- $C_1$ - $C_4$ -alkyl, where heterocyclyl in the aforementioned radicals may have one, two or three heteroatoms selected from S, O and N, and

where the last 6 radicals may have, on the heterocycle or on the phenyl ring, 1, 2 or 3 substituents Rb which are each independently selected from optionally substituted C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>4</sub>-C<sub>10</sub>-bicycloalkyl and C<sub>6</sub>-C<sub>10</sub>tricycloalkyl, where the last three groups may optionally be substituted by halogen or C<sub>1</sub>-C<sub>4</sub>-alkyl, halogen, CN, OR<sup>1</sup>, NR<sup>2</sup>R<sup>3</sup>, NO<sub>2</sub>, SR<sup>4</sup>, SO<sub>2</sub>R<sup>5</sup>, CONR<sup>2</sup>R<sup>3</sup>, SO<sub>2</sub>NR<sup>2</sup>R<sup>3</sup>, COOR<sup>5</sup>, COR<sup>6</sup>, O-COR<sup>6</sup>, 5- or 6-membered heterocyclyl having 1, 2 or 3 heteroatoms selected from O, S and N, and phenyl, where phenyl and heterocyclyl in the last two substituents Rb may optionally bear one or two substituents which are each independently selected from C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, NR<sup>2</sup>R<sup>3</sup>, CN, C<sub>1</sub>-C<sub>2</sub>-fluoroalkyl and halogen, and where 2 substituents Rb bonded to adjacent carbon atoms of the aromatic radical may together be C<sub>3</sub>- or C<sub>4</sub>-alkylene, or, together with the carbon atoms to which they are bonded, may be a fused-on, unsaturated 5- or 6-membered carbocycle or a 5- or 6-membered heterocycle having 1 or 2 nitrogen atoms as ring members; or

R<sup>a</sup> is an E-Ar group wherein E is a bond or linear or branched alkylene having from 1 to 4 carbon atoms and in particular (CH<sub>2</sub>)<sub>p</sub> where p is 0, 1, 2, 3 or 4, and Ar is selected from phenyl, naphthyl and 5- or 6-membered heteroaryl which has one, two or three heteroatoms selected from S, O and N as ring members and which may optionally have 1, 2 or 3 of the aforementioned substituents R<sup>b</sup>; or



is a saturated monocyclic nitrogen heterocycle having from 5 to 7 ring atoms which bears a fused-on benzene ring of the formula

where \* denotes the bonding sites to the saturated monocyclic heterocycle; R<sup>c</sup> may be the same or different and is as defined for R<sup>b</sup>, and n is 0, 1, 2 or 3;

where may optionally also have 1, 2, 3 or 4 further C<sub>1</sub>-C<sub>4</sub>-alkyl groups as substituents;

the physiologically acceptable acid addition salts of this compound and the tautomer of the formula I'

$$R \xrightarrow{-B} A - D - N Z \qquad (I')$$

where R is halogen, an O-R¹ group where R¹ is as defined above, or an O-C(O)R⁰ group where R⁰ is hydrogen, optionally substituted  $C_1$ - $C_6$ -alkyl, benzyl or phenyl, where the last two radicals are optionally substituted by one or two radicals which are each independently selected from  $C_1$ - $C_4$ -alkyl, OH,  $C_1$ - $C_4$ -alkoxy, NR²R³, CN,  $C_1$ - $C_2$ -fluoroalkyl or halogen, and the physiologically acceptable acid addition salts of the tautomer l'.

- 2. (Previously Presented) A compound of the general formula I or I' as claimed in claim 1, where R\*, R\*, together with the carbon atoms to which they are bonded, are a fused phenyl ring or a fused 5- or 6-membered aromatic heterocycle which has 1, 2, 3 or 4 heteroatoms which are selected from N, O and S, where the fused phenyl ring and the fused aromatic heterocycle may have 1, 2 or 3 substituents which are selected from C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-hydroxyalkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, CN, OR¹, NR²R³, NO<sub>2</sub>, SR⁴, SO<sub>2</sub>R⁴, SO<sub>2</sub>NR²R³, CONR²R³, COOR⁵, COR⁶, C<sub>1</sub>-C<sub>2</sub>-fluoroalkyl, C<sub>1</sub>-C<sub>2</sub>-fluoroalkoxy, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>2</sub>-C<sub>6</sub>-alkenyloxy, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl and halogen; where R¹, R², R³, R⁴, R⁵ and R⁶ are each independently as defined above.
- (Currently Amended) A compound as claimed in either of the preceding claims
  claim 1, where D in the formulae I and I' is a (CH₂)<sub>k</sub> group or a C(O)(CH₂)<sub>i</sub> group,
  where k is 3, 4, 5 or 6 and I is 2, 3, 4 or 5.
- 4. (Currently Amended) A compound as claimed in any of the preceding claims claim 1, where A is N-C(O) in which the carbon atom is bonded to the variable B.

- 5. (Previously Presented) A compound as claimed in claim 4, where B is CH<sub>2</sub>.
- (Currently Amended) A compound of the general formula I or I' as claimed in any
  of the preceding claims claim 1, where

is a radical of the formula 
$$R^e$$
 where  $R^a$  is as defined above, and

- J is CH<sub>2</sub>, CH<sub>2</sub>-CH<sub>2</sub> or CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>;
- X is CH or N and
- Y is CH<sub>2</sub>, CH<sub>2</sub>-CH<sub>2</sub> or CH<sub>2</sub>-CH<sub>2</sub>, or Y-X together is CH=C or CH<sub>2</sub>-CH=C;
- R<sup>e</sup> is hydrogen or C<sub>1</sub>-C<sub>4</sub>-alkyl.
- 7. (Previously Presented) A compound as claimed in claim 6, where J is CH<sub>2</sub>-CH<sub>2</sub> and Y is CH<sub>2</sub>.
- 8. (Currently Amended) A compound as claimed in claim 6 [[or 7]], where X is N.
- 9. (Previously Presented) A compound of the general formula I or I' as claimed in claim 6, where R<sup>a</sup> is an E-Ar group where E and Ar are each as defined above.
- 10. (Previously Presented) A compound as claimed in claim 9, where E is a bond.
- 11. (Previously Presented) A compound as claimed in claim 10, where Ar is phenyl, pyridyl, pyrimidinyl or s-triazinyl, each of which has 1, 2 or 3 of the aforementioned R<sup>b</sup> radicals.
- 12. (Previously Presented) A compound as claimed in claim 9, where E is CH2.
- 13. (Previously Presented) A compound as claimed in claim 12, where Ar is phenyl, naphthyl, pyridyl, pyridinyl, pyrazinyl, pyridazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1-oxa-3,4-diazolyl or 1-thia-3,4-diazolyl, each of which is unsubstituted or may have 1, 2 or 3 of the abovementioned R<sup>b</sup> radicals.

- 14. (Currently Amended) A compound as claimed in any of claims claim 6 [[to 8]], where R<sup>a</sup> is C<sub>1</sub>-C<sub>10</sub>-alkyl, C<sub>2</sub>-C<sub>10</sub>-alkenyl, C<sub>3</sub>-C<sub>10</sub>-cycloalkyl, C<sub>3</sub>-C<sub>10</sub>-cycloalkyl-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>3</sub>-C<sub>10</sub>-beterocycloalkylcarbonyl-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>3</sub>-C<sub>10</sub>-heterocycloalkylcarbonyl-C<sub>1</sub>-C<sub>4</sub>-alkyl.
- 15. (Previously Presented) A compound of the general formula I-Aa

$$O = A - D - N X - R^{a}$$

$$(I-Aa)$$

$$(R^{d})_{m}$$

where Ra, A, B and D are each as defined in claim 1;

m is 0, 1, 2 or 3;

R<sup>d</sup> are each independently  $C_1$ – $C_4$ -alkyl,  $C_1$ – $C_4$ -hydroxyalkyl,  $C_1$ – $C_4$ -alkoxy- $C_1$ - $C_4$ -alkyl, CN, OR<sup>1</sup>, NR<sup>2</sup>R<sup>3</sup>, NO<sub>2</sub>, SR<sup>4</sup>, SO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NR<sup>2</sup>R<sup>3</sup>, CONR<sup>2</sup>R<sup>3</sup>, COOR<sup>5</sup>, COR<sup>6</sup>, C<sub>1</sub>–C<sub>2</sub>-fluoroalkyl, C<sub>1</sub>–C<sub>2</sub>-fluoroalkoxy, C<sub>2</sub>–C<sub>6</sub>-alkenyl, C<sub>2</sub>–C<sub>6</sub>-alkynyl, C<sub>2</sub>–C<sub>6</sub>-alkenyloxy, C<sub>2</sub>–C<sub>6</sub>-alkynyloxy, C<sub>3</sub>–C<sub>6</sub>-cycloalkyl, C<sub>3</sub>–C<sub>6</sub>-cycloalkyl or halogen, where R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are each as defined in claim 1;

J is CH<sub>2</sub>, CH<sub>2</sub>-CH<sub>2</sub> or CH<sub>2</sub>-CH<sub>2</sub>-CH<sub>2</sub>;

X is CH or N and

Y is CH<sub>2</sub>, CH<sub>2</sub>-CH<sub>2</sub> or CH<sub>2</sub>-CH<sub>2</sub>, or Y-X together is CH=C or CH<sub>2</sub>-CH=C;

the physiologically acceptable acid addition salts of this compound and the tautomer of the formula I-A'a

$$R \xrightarrow{B} A - D - N \xrightarrow{J} X - R^{a}$$

$$(I-A'a)$$

$$(R^{d})_{m}$$

where R is as defined in claim 1 and the physiologically acceptable acid addition salts of the tautomer la'.

16. (Previously Presented) A compound of the formula I-Ba

$$O = \begin{pmatrix} O \\ N - D - N \end{pmatrix} X - R^{a}$$
 (I-Ba)

where Ra and D are each as defined in claim 1;

- $R^{x1}$ ,  $R^{y1}$  are each independently hydrogen, halogen, optionally substituted  $C_1$ - $C_6$ -alkyl,  $C_1$ - $C_6$ -alkoxy,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_3$ - $C_6$ -cycloalkyl- $C_1$ - $C_4$ -alkyloxy or  $C_3$ - $C_6$ -cycloalkyl;
- J is CH<sub>2</sub>, CH<sub>2</sub>-CH<sub>2</sub> or CH<sub>2</sub>-CH<sub>2</sub>;
- X is CH or N and
- Y is CH<sub>2</sub>, CH<sub>2</sub>-CH<sub>2</sub> or CH<sub>2</sub>-CH<sub>2</sub>, or Y-X together is CH=C or CH<sub>2</sub>-CH=C;

and the physiologically acceptable acid addition salts of the compound I-Ba.

- 17. (Currently Amended) A compound as claimed in claim 15 [[or 16]], where J is CH<sub>2</sub>-CH<sub>2</sub> and Y is CH<sub>2</sub>.
- 18. (Currently Amended) A compound as claimed in any of claims claim 15 [[to 17]], where X is N.
- (Currently Amended) A compound of the general formula I or I' as claimed in any
  of claims claim 15 [[to 18]], where R<sup>a</sup> is an E-Ar group in which E and Ar are each
  as defined above.
- 20. (Previously Presented) A compound as claimed in claim 19, where E is a bond.
- (Previously Presented) A compound as claimed in claim 20, where Ar is phenyl, pyridyl, pyrimidinyl or s-triazinyl, each of which has 1, 2 or 3 of the aforementioned R<sup>b</sup> radicals.

- 22. (Previously Presented) A compound as claimed in claim 19, where E is CH2.
- 23. (Previously Presented) A compound as claimed in claim 22, where Ar is phenyl, naphthyl, pyridyl, pyridinyl, pyrazinyl, pyridazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1-oxa-3,4-diazolyl or 1-thia-3,4
  - diazolyl, each of which is unsubstituted or may have 1, 2 or 3 of the abovementioned  $R^{\text{b}}$  radicals
- 24. (Currently Amended) A compound as claimed in any of claims claim 15 [[to 18]], where  $R^a$  is  $C_1$ - $C_{10}$ -alkyl,  $C_2$ - $C_{10}$ -alkenyl,  $C_3$ - $C_{10}$ -cycloalkyl,  $C_3$ - $C_{10}$ -cycloalkylcarbonyl- $C_1$ - $C_4$ -alkyl,  $C_3$ - $C_{10}$ -heterocycloalkylcarbonyl- $C_1$ - $C_4$ -alkyl.
- 25. (Currently Amended) A pharmaceutical composition comprising at least one active ingredient which is selected from compounds of the formula I, the tautomers of the formula I', the physiologically tolerated acid addition salts of the compounds I and the physiologically tolerated acid addition salts of the tautomers of the formula I' as claimed in any of claims claim 1 [[to 24]], optionally together with physiologically acceptable carriers and/or excipients.
- 26. (Currently Amended) The use of active ingredients which are selected from compounds of the formula I, the tautomers of the formula I', the physiologically tolerated acid addition salts of the compounds I and the physiologically tolerated acid addition salts of the tautomers of the formula I' as claimed in any of claims claim 1 [[to 24]] for producing a pharmaceutical composition for treating diseases which respond to the influence of dopamine D<sub>3</sub> receptor antagonists or agonists.
- 27. (Previously Presented) The use as claimed in claim 26 for treating diseases of the central nervous system.
- 28. (Previously Presented) The use as claimed in claim 26 for treating kidney function disorders.